检索结果-内蒙古大学图书馆

arXiv 2017年

作者： Li, Songzi Rizzo, Maria L. Biostatistics and Programming Department Pharmaceutical Product Deparment LLC WilmingtonNC28401 Dept. of Mathematics & Statistics Bowling Green State University Bowling GreenOH43403 United States

We propose a new class of distribution-based clustering algorithms, called k-groups, based on energy distance between samples. The energy distance clustering criterion assigns observations to clusters according to a multi-sample energy statistic that measures the distance between distributions. The energy distance determines a consistent test for equality of distributions, and it is based on a population distance that characterizes equality of distributions. The k-groups procedure therefore generalizes the k-means method, which separates clusters that have different means. We propose two k-groups algorithms: k-groups by first variation;and k-groups by second variation. The implementation of k-groups is partly based on Hartigan and Wong's algorithm for k-means. The algorithm is generalized from moving one point on each iteration (first variation) to moving m (m > 1) points. For univariate data, we prove that Hartigan and Wong's k-means algorithm is a special case of k-groups by first variation. The simulation results from univariate and multivariate cases show that our k-groups algorithms perform as well as Hartigan and Wong's k-means algorithm when clusters are well-separated and normally distributed. Moreover, both k-groups algorithms perform better than k-means when data does not have a finite first moment or data has strong skewness and heavy tails. For non-spherical clusters, both k-groups algorithms performed better than k-means in high dimension, and k-groups by first variation is consistent as dimension increases. In a case study on dermatology data with 34 features, both k-groups algorithms performed better than k-means. Copyright © 2017, The Authors. All rights reserved.

关键词： Cluster analysis

来源：评论

学校读者我要写书评

暂无评论

819P Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial

引用

Annals of Oncology 2022年 33卷 S921-S922页

作者： P. Nathan J.J. Grob R. Dummer P.A. Ascierto A. Ribas C. Robert D. Schadendorf K.T. Flaherty H.A. Tawbi A. Hauschild M. Mandala R. Shah H. Banerjee R.P. Sarkar M.R. Lau G.V. Long Department of Medical Oncology Mount Vernon Cancer Centre East and North Herts NHS Trust Northwood UK Department of Dermatology and Skin Cancers Timone Hospital AP-HM Aix-Marseille University Marseille France Department of Dermatology University Hospital Zürich Skin Cancer Center Zurich Switzerland Department of Melanoma Cancer Immunotherapy & Developmental Therapeutics Istituto Nazionale Tumori - IRCCS - Fondazione Pascale Naples Italy Department of Medicine Jonsson Comprehensive Cancer Center UCLA Los Angeles CA USA Department of Dermatology Gustave Roussy Cancer Campus Grand Paris & University Paris-Saclay Villejiuf France Department of Dermatology University Hospital Essen and German Cancer Consortium Essen Germany Dana-Farber Cancer Centre Harvard Medical School and Massachusetts General Hospital Boston MA USA Melanoma Medical Oncology Department The University of Texas MD Anderson Cancer Center Houston TX USA Department of Dermatology University Hospital Schleswig-Holstein Kiel Germany Department of Medical Oncology University of Perugia and Papa Giovanni XXIII Cancer Center Hospital Perugia Italy US Medical Affairs - Melanoma Novartis Pharmaceuticals Corporation East Hanover NJ USA Analytics - Global Health Novartis Pharmaceuticals Corporation East Hanover NJ USA Biostatistics and Statistical Programming Novartis Healthcare Pvt Ltd. Hyderabad India Medical Affairs Novartis Pharma AG Basel Switzerland Department of Medical Oncology Melanoma Institute Australia The University of Sydney and Royal North Shore and Mater Hospitals North Sydney NSW Australia

来源：评论

学校读者我要写书评

暂无评论

90TiP Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6)

引用

Annals of Oncology 2022年 33卷 S162-S163页

作者： G. Rossi E. Brain A. Dueck H. De Swert S.I. Marreaud A. Partridge C. Herold H. Vachon T. Spanic A. Arahmani T. Verbiest L. Wang T. Goulioti B. Malanda L.A. Carey S. Anneheim G. Paux C. Poncet D. Cameron Research & Development Department Breast International Group (BIG) - AISBL Brussels Belgium Department of Medical Oncology Institut Curie - Hôpital René Huguenin Saint-Claud France Alliance Foundation Trials (AFT) Boston MA USA Research Operations Department Breast International Group (BIG) - AISBL Brussels Belgium Medical Department European Organisation for Research and Treatment of Cancer (EORTC) Brussels Belgium Department of Medical Oncology Alliance Foundation Trials (AFT) Boston MA USA Oncology Sanofi Genzyme Cambridge MA USA Quality of Life Department European Organisation for Research and Treatment of Cancer (EORTC) Brussels Belgium Europa Donna − the European Breast Cancer Coalition Milan Italy Research Operations Department Breast International Group (BIG)-AISBL Brussels Belgium Data Management European Organisation for Research and Treatment of Cancer (EORTC) Brussels Belgium Translational Medicine and Early Development Sanofi Boston MA USA Breast International Group (BIG) - AISBL Brussels Belgium Projects Direction European Organisation for Research and Treatment of Cancer (EORTC) Brussels Belgium Division of Medical Oncology North Carolina Lineberger Comprehensive Cancer Center Chapel Hill NC USA Oncology Development Sanofi-Aventis Recherche et Developpement Vitry-sur-Seine France Biostatistics and Programming Sanofi-Aventis U.S. LLC Bridgewater MA USA Statistics European Organisation for Research and Treatment of Cancer (EORTC) Brussels Belgium University of Edinburgh Cancer Research Centre Institute of Genetics and Cancer Western General Hospital Edinburgh UK

来源：评论

学校读者我要写书评

暂无评论

277MO SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2- metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study

引用

Annals of Oncology 2020年 31卷 S351-S351页

作者： S. Chandarlapaty A. Bardia S. Lord H. Linden V. Pelekanou N. Ternes J. Ming V. Boutet E. Boitier A. Gosselin J. Sang Lee W. Dos-Santos Bele A. Protopopov M. Celanovic A-L. Bauchet M. Campone Medicine Memorial Sloan Kettering Cancer Center New York NY USA Medical Oncology Massachusetts General Hospital Harvard Medical School Boston MA USA Department of Oncology University of Oxford Churchill Hospital Oxford UK Department of Medicine University of Washington Medical Center Seattle WA USA Clinical Precision Oncology-Tranlsational Medicine Early Development Sanofi Cambridge MA USA Biostatistics and Programming Sanofi Paris France Oncology Sanofi Bridgewater NJ USA TMED & Biomarkers & Clinical Bioanalyses Sanofi Paris France Precision Oncology Sanofi Cambridge MA USA Molecular Profiling Precision Oncology Sanofi Paris France Oncology-OMD Sanofi Cambridge MA USA Medical Oncology Institut de Cancérologie de l'Ouest Saint-Herblain France

来源：评论

学校读者我要写书评

暂无评论

19P Therapeutic targets in non-small cell lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expression and its associated molecular landscape

引用

Annals of Oncology 2021年 32卷 S1381-S1381页

作者： J. Adam A-M. Lefebvre C. Nicolazzi C. Larois F. Attenot F. Falda-Buscaiot C. Dib N. Ternès N. Masson A-L. Bauchet B. Demers M. Chadjaa S. Sidhu C. Combeau J-C. Soria J-Y. Scoazec S. Naimi E. Angevin C. Henry Pathology Institut Gustave Roussy Villejuif France Molecular Histopathology and Bio-Imaging Translational Sciences Unit Sanofi Chilly-Mazarin France Oncology Research Sanofi R&D Sanofi Vitry-sur-Seine France Molecular Histopathology and Bio-Imaging Translational Sciences Unit Sanofi Vitry-sur-Seine France Oncology Research Department Sanofi Vitry-sur-Seine France Early Oncology Sanofi Vitry-sur-Seine France Oncology Sanofi Vitry-sur-Seine France Biostatistics and Programming Sanofi Chilly-Mazarin France IT&M Stats Sanofi Paris France Translational Medicine and Early Development/Biomarkers and Clinical Bioanalyses Sanofi Chilly-Mazarin France Early Development Oncology Sanofi Vitry-sur-Seine France Oncology Development Sanofi Vitry-sur-Seine France Pharmacology Sanofi Vitry-sur-Seine France Translational Medicine and Early Development Sanofi Vitry-sur-Seine France Drug development Department Institut Gustave Roussy Villejuif France Université Paris Saclay Institut Gustave Roussy Villejuif France Molecular and Digital Histopathology Research and Development Sanofi Vitry-sur-Seine France Early Drug Development Institut Gustave Roussy Villejuif France Oncology R&D (research) Sanofi Vitry-sur-Seine France

来源：评论

学校读者我要写书评

暂无评论

069 High baseline serum IL-6 identifies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response

引用

Rheumatology 2019年第SUPPLEMENT_3期58卷

作者： Boyapati, Anita Msihid, Jérôme Schwartzman, Sergio Choy, Ernest Burmester, Gerd R Lam, Gordon Kimura, Toshio Sadeh, Jonathan Graham, Neil M H Precision Medicine Regeneron Pharmaceuticals Inc. Tarrytown NY Biostatistics and Programming Sanofi Chilly-Mazarin FRANCE Rheumatology Hospital for Special Surgery New York NY CREATE Center Cardiff University School of Medicine Cardiff UNITED KINGDOM Rheumatology and Clinical Immunology Charité University Medicine Berlin GERMANY Rheumatology Atrium Health Charlotte NC Medical Analytics Regeneron Pharmaceuticals Inc. Tarrytown NY Immunology and Inflammation Franchise Sanofi Genzyme Bridgewater NJ Immunology and Inflammation Regeneron Pharmaceuticals Inc. Tarrytown NY

来源：评论

学校读者我要写书评

暂无评论

F110. SYMPTOMATIC REMISSION WITH PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION IN SCHIZOPHRENIA PATIENTS IN A CLINICAL PRACTICE SETTING

引用

Schizophrenia Bulletin 2019年第SUPPLEMENT_2期45卷 S295–S296页

作者： Garcia-Portilla, M P Llorca, P M Maina, G Bozikas, V P Devrimci-Ozguven, H Kim, S W Bergmans, P Usankova, I Cherubin, P Najarian, Dean Pungor, K CIBERSAM (G05) University of Oviedo CHRU Clermont-Ferrand Pôle Psychiatrie France SCDU Psichiatria AOU San Luigi Gonzaga Università degli Studi di Torino School of Medicine Aristotle University of Thessaloniki Ankara University School of Medicine Chonnam National University Medical School Janssen Cilag Biostatistics & Programming Breda Johnson & Johnson EMEA Medical Affairs Organization Moscow Janssen Cilag EMEA Medical Affairs Issy-les-Moulineaux Janssen Scientific Affairs Janssen Cilag EMEA Medical Affairs Dusseldorf

Background Symptomatic remission (SR) is an important outcome for schizophrenia patients [1]. In pivotal trials, paliperidone 3-monthly formulation (PP3M) demonstrated favorable efficacy and tolerability in schizophrenia, including achievement of SR [2–4]. However, due to the selective nature of randomized clinical trials, populations studied may not be entirely representative of schizophrenia patients in real life. Methods A prospective, single-arm, open-label, 52-week study (REMISSIO) was conducted in a naturalistic setting to assess the impact of conversion from paliperidone palmitate 1-month formulation (PP1M) to PP3M in patients with clinically stable schizophrenia. Patients aged 18–50 years with schizophrenia (DSM-5) were eligible to participate if they had been adequately treated with PP1M for ≥4 months (the last 2 doses of PP1M being the same) and had a baseline Positive and Negative Syndrome Scale (PANSS) total score <70. The initial dose of PP3M and subsequent dose changes (possible at clinicians’ discretion) were made according to the product label [5]. The primary outcome was the number of patients who achieved SR (score ≤3 on PANSS items P1, P2, P3, N1, N4, N6, G5, and G9, maintained for ≥6 months) at the last observation carried forward (LOCF) endpoint [1]. Other outcomes included PANSS total and subscores, Clinical Global Impression of Change (CGI-C), and adverse events (AEs). The intent-to-treat (ITT) population comprised 305 patients from Europe, Middle East and Asia, who had received ≥1 dose of PP3M. Treatment response analyses were performed on the efficacy ITT population (n=303). Endpoint analysis using LOCF was performed, in addition to observed case analysis. Results Patients had a mean (standard deviation; SD) age of 36.5 (8.0) years, 66% were male, and mean (SD) time since schizophrenia diagnosis was 9.2 (7.3) years. A total of 291 patients completed the 52-week study period. Mean (SD) first dose of PP3M was 363.6 (115.4) mg and mean (SD) mod

关键词：

来源：评论

学校读者我要写书评

暂无评论

806P Updated toxicity profile and relapse-free survival outcomes using an adapted pyrexia management algorithm in patients with resected stage III BRAF V600E/K-mutant melanoma treated with adjuvant dabrafenib plus trametinib in COMBI-APlus

引用

Annals of Oncology 2022年 33卷 S914-S914页

作者： M. Del Vecchio V.G. Atkinson B. Ryll A.M. Menzies F. Aubin V. Chiarion Sileni V. Ferraresi T. Lesimple G. Rinaldi P. Saiag C. Robert C. Dutriaux H.J. Gogas L. Demidov A. Gupta H. Banerjee S. Sudhir F. Miranda M.R. Lau J.J. Grob Department of Medical Oncology and Hematology Unit of Melanoma Medical Oncology Fondazione IRCCS - Istituto Nazionale dei Tumori Milan Italy Division of Cancer Services Princess Alexandra Hospital - University of Queensland Qld Australia Melanoma Department Melanoma Patient Network Europe MPNE Uppsala Sweden Department of Medical Oncology Melanoma Institute Australia The University of Sydney Royal North Shore and Mater Hospitals Sydney NSW Australia Department of Dermatology University Hospital and Inserm Besançon France Azienda Ospedaliera Di Padova Padua Italy Sarcomas and Rare Tumors Unit IRCCS Regina Elena National Cancer Institute (IRE) Rome Italy Département d'Oncologie Médicale CLCC Eugène Marquis Rennes France Department of Surgical Oncological and Oral Sciences Section of Oncology University of Palermo Palermo Italy Service de Dermatologie Générale et Oncologique Hôpital A Paré Assistance Publique-Hôpitaux de Paris Boulogne-Billancourt France Department of Medicine Gustave Roussy and Paris-Saclay University Villejiuf France Department of Dermatology University Hospital of Bordeaux / CHU De Bordeaux Hospital Saint-André Bordeaux France First Department of Internal Medicine Laiko General Hospital National and Kapodistrian University of Athens School of Medicine Athens Greece Tumor Biotherapy N.N. Blokhin Russian Cancer Research Center Moscow Russian Federation Medical Oncology The Christie NHS Foundation Trust Manchester UK Analytics Novartis Pharmaceuticals Corporation East Hanover NJ USA Biostatistics & Statistical Programming Novartis Healthcare Private Limited Hyderabad India Clinical Operations Novartis Pharmaceuticals Corporation East Hanover NJ USA Medical Affairs Department Novartis Pharma AG Basel Switzerland Dermatology and Skin Cancer Department Aix-Marseille University Marseille France

来源：评论

学校读者我要写书评

暂无评论

Performance evaluation of practice courses using fuzzy cognitive maps

Performance evaluation of practice courses using fuzzy cogni...

引用

International Conference on Information Technology Based Higher Education and Training, ITHET

作者： Ahmet Albayrak Muammer Albayrak Department of Computer Programming Karadeniz Technical University Trabzon Turkey Department of Biostatistics and Medical Informatics Karadeniz Technical University Trabzon Turkey

ISBN: (纸本)9781509007790

In this study, the effect of practical courses (especially robotics) on students' success is evaluated using fuzzy cognitive maps. This study particularly focuses on how practical courses increase the learning achievements in vocational schools. For this purpose, students and academicians were chosen as stakeholders for this study. Student were selected from departments of machine, electronic and computer. In total views of 30 students were taken and evaluated using fuzzy cognitive maps before the study. Students were studied on three projects within this study. These projects are autonomous cleaning robot, chameleon robot and sumo wrestler robot. Each robot was developed by a group consisting of ten students. Three main outputs determined to be gained by students in the robot development process as sensor calibration, improvement of mechanical systems and software optimization. These outputs are also among the output concepts of the fuzzy cognitive map. Sensor calibration, improvement of the mechanical systems and optimization of the software are the critical tasks respectively for the student groups of electronics, machine and computer. Each student group shared students of their departments homogeneously. Academicians were selected as one from each department. Fuzzy cognitive maps' survey applied to 15 academicians. After the design and development processes of robots, students and academicians views re-evaluated. It was observed clearly from the comparison of the results that, learning achievement, desire to learn, desire to interdisciplinary collaboration, self-confidence, interest in robotic technologies, satisfaction and desire to give priority to practical training in other subjects are increased by %45, %63, %42, %74, %85, %88 and %76 respectively.

关键词： Mathematical model Robot sensing systems Fuzzy cognitive maps Training Stakeholders

来源：评论

学校读者我要写书评

暂无评论

222 Efficacy of sarilumab in patients with rheumatoid arthritis who previously received sarilumab or tocilizumab

引用

Rheumatology 2018年第SUPPL_3期57卷

作者： Emery, Paul van Hoogstraten, Hubert Jayawardena, Shyamalie Mangan, Erin Cejas, Paula Verschueren, Patrick Leeds Institute of Rheumatic and Musculoskeletal Medicine University of Leeds Leeds UNITED KINGDOM Global Medical Affairs Sanofi Genzyme Bridgewater NJ USA Biostatistics and Programming Sanofi Bridgewater NJ USA Medical Affairs Regeneron Pharmaceuticals Inc. Tarrytown NY USA Reumatología Hospital Quirónsalud Infanta Luisa Sevilla SPAIN Division of Rheumatology University Hospital Leuven Leuven BELGIUM.

来源：评论

学校读者我要写书评

暂无评论

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案：

请选择收藏分类：

通借通还

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：